InDevR's ViroPrep(TM) AI for Rapid Quantification of Egg-Grown Influenza
Published: Sep 06, 2012
BOULDER, CO--(Marketwire - September 06, 2012) -
With the majority of global seasonal flu vaccine manufactured in eggs, there is an urgent need to improve the production process to avoid shortages and delays, so much so that the 2011 Strategic Plan of the United States Food and Drug Administration (FDA) emphasizes reducing costs, improving efficiency and enhancing production of vaccines. Many methods used today, such as plaque titer assays, only determine infectivity levels and require days or weeks to carry out, significantly delaying vaccine development and manufacturing. None, however, are capable of quantifying intact virus, data that can be critical at key steps including seed stock characterization and process optimization. Understanding the total number of intact viral particles, regardless of infectivity, will facilitate immediate and informed decisions at numerous points across the vaccine development and manufacturing continuum.
According to Dr. Michael Artinger, Vice President of Commercial Operations at InDevR, "ViroPrep and ViroCyt address an essential requirement within the vaccine community by making same day elucidation of total particle count possible. InDevR looks forward to continuing to create innovative solutions that solve the many real world challenges of getting safe and effective vaccines to patients."
Catarina Flyborg, Bioprocess Product Marketing Leader, GE Healthcare Life Sciences said, "GE Healthcare's Capto Core 700 brings significant advantages in productivity and process economy over traditional techniques for influenza virus purification, making it an ideal choice for InDevR's ViroPrep AI. We are delighted that Capto Core 700 has been selected by InDevR for this exciting new application." To learn more about the ViroCyt 2100 and the ViroPrep AI technologies, please visit www.indevr.com.
InDevR develops breakthrough life science instrumentation and assays for scientists and researchers, with a primary focus on the issues associated with virus quantification and pathogen detection. InDevR's lead product is a flow cytometer called the ViroCyt 2100 which has been optimized to rapidly quantify micro-organisms such as viruses in applications including vaccine manufacturing, antiviral research, protein expression and other areas important to human health. InDevR's ampliPHOX® is an innovative new colorimetric detection system that makes the power of lower density microarrays available to a broad range of researchers developing both nucleic acid and protein multiplexed assays. For more information, please visit www.indevr.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.